Lu Jingchao, Hao Jie, Du Hong, Xiao Bing, Li Yue, Yang Xiuchun, Cui Wei
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang City, China.
Cell Physiol Biochem. 2016;39(1):47-60. doi: 10.1159/000445604. Epub 2016 Jun 20.
MMPs/TIMPs system is well known to play important roles in pressure overload-induced cardiac remodeling, and Amlodipine and Atorvastatin have been showed to exert favourable protective effects on cardiovascular disease, however, it is not clear whether Amlodipine and Atorvastatin can improve hypertensive cardiac remodeling and whether the MMPs/TIMPs system is involved. The present study aims to answer these questions.
36 weeks old male spontaneous hypertension (SHR) rats were randomly divided into four groups: 1). SHR control group, 2). Amlodipine alone (10 mg/kg/d) group, 3). Atorvastatin alone (10 mg/kg/d) group, 4).Combination of Amlodipine and Atorvastatin (10 mg/kg/d for each) group. Same gender, weight and age of Wistar-Kyoto (WKY) rats with normal blood pressure were used as normal control. Drugs were administered by oral gavage over 12 weeks. The blood pressure and left ventricle mass index were measured. Enzyme activity of MMP-2 and MMP-9 was assessed with Gelatin zymography. MMP-2, MMP-9, TIMP-1 and TIMP-2 mRNA and protein expression was studied by RT-PCR and Western blot. Single factor ANOVA and LSD-t test were used in statistical analysis.
Treatment with Amlodipine alone or combination with atorvastatin significantly decreased blood pressure, left ventricle mass index in SHR rats (P < 0.05 for both). Compared with WKY rats, the myocardial levels of MMP-2, MMP-9 mRNA, protein and enzyme activity were significantly increased (P<0.05). Amlodipine alone, Atorvastatin alone, and combination of the two all reduced MMP-2 and MMP-9 mRNA, protein and enzyme activity, with the best effects seen in the combination. Compared with WKY rats, the myocardial levels of TIMP-1 mRNA and protein were significantly increased (P<0.05), however, there was no difference in levels of TIMP-2. Neither Amlodipine alone, Atorvastatin alone, nor combination of the two drugs significantly affect the expression of TIMP-1 or TIMP-2.
Amlodipine and Atorvastatin could improve ventricular remodeling in SHR rats through intervention with the imbalance of MMP-2/TIMP-2 and MMP-9/TIMP-1 system.
众所周知,基质金属蛋白酶/金属蛋白酶组织抑制剂(MMPs/TIMPs)系统在压力超负荷诱导的心脏重塑中起重要作用,氨氯地平和阿托伐他汀已被证明对心血管疾病具有良好的保护作用,然而,尚不清楚氨氯地平和阿托伐他汀是否能改善高血压性心脏重塑以及MMPs/TIMPs系统是否参与其中。本研究旨在回答这些问题。
将36周龄雄性自发性高血压(SHR)大鼠随机分为四组:1)SHR对照组;2)氨氯地平单药组(10mg/kg/d);3)阿托伐他汀单药组(10mg/kg/d);4)氨氯地平和阿托伐他汀联合组(各10mg/kg/d)。选取性别、体重和年龄相同的血压正常的Wistar-Kyoto(WKY)大鼠作为正常对照组。通过灌胃给药12周。测量血压和左心室质量指数。采用明胶酶谱法评估基质金属蛋白酶-2(MMP-2)和基质金属蛋白酶-9(MMP-9)的酶活性。通过逆转录聚合酶链反应(RT-PCR)和蛋白质免疫印迹法研究MMP-2、MMP-9、金属蛋白酶组织抑制剂-1(TIMP-1)和金属蛋白酶组织抑制剂-2(TIMP-2)的mRNA和蛋白表达。采用单因素方差分析和LSD-t检验进行统计学分析。
单独使用氨氯地平或与阿托伐他汀联合治疗可显著降低SHR大鼠的血压和左心室质量指数(两者P均<0.05)。与WKY大鼠相比,SHR大鼠心肌中MMP-2、MMP-9的mRNA、蛋白水平及酶活性显著升高(P<0.05)。单独使用氨氯地平、单独使用阿托伐他汀以及两者联合使用均降低了MMP-2和MMP-9的mRNA、蛋白水平及酶活性,联合使用效果最佳。与WKY大鼠相比,SHR大鼠心肌中TIMP-1的mRNA和蛋白水平显著升高(P<0.05),然而,TIMP-2水平无差异。单独使用氨氯地平、单独使用阿托伐他汀以及两者联合使用均未显著影响TIMP-1或TIMP-2的表达。
氨氯地平和阿托伐他汀可通过干预MMP-2/TIMP-2和MMP-9/TIMP-1系统失衡来改善SHR大鼠的心室重塑。